CAR-T-cell therapies
Vreugdenburg T, Moshi MR, Min M, Nicolopoulos K, Stringer D
Record ID 32018005506
English
Original Title:
The CAR T cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B cell acute lymphoblastic leukaemia, diffuse large B cell lymphoma and primary mediastinal B cell lymphoma
Details
Project Status:
Ongoing
URL for project:
https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html
URL for protocol:
https://www.bag.admin.ch/dam/bag/en/dokumente/kuv-leistungen/leistungen-und-tarife/hta/berichte/h0075cart-hta-protocol.pdf.download.pdf/h0075cart-hta-protocol.pdf
Anticipated Publish Date:
2024
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Switzerland
MeSH Terms
- Leukemia, B-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Receptors, Chimeric Antigen
- Immunotherapy, Adoptive
- Antineoplastic Agents, Immunological
- Receptors, Antigen, T-Cell
Keywords
- CAR T cell therapies
- CAR-T
- tisagenlecleucel
- Yescarta®
- Kymriah®
- diffuse large B cell lymphoma
- lymphoma
- B cell acute lymphocytic leukaemia
- leukaemia
- primary mediastinal B cell lymphoma
- axicabtagene ciloleucel
- PROMs
- efficacy
- effectiveness
- safety
- costs
- economics
- cost-effectiveness
- budget impact
- legal
- social
- ethical
- organisational
Contact
Organisation Name:
Swiss Federal Office of Public Health (FOPH)
Contact Address:
Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name:
Stephanie Vollenweider
Contact Email:
hta@bag.admin.ch
Copyright:
Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.